YMAB | Y-mAbs Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	10.35 - 11.11
52 Week Range	5.29 - 20.90
Beta	0.43
Implied Volatility	130.87%
IV Rank	51.53%
Day's Volume	219,968
Average Volume	262,487
Shares Outstanding	44,789,100
Market Cap	472,077,114
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-09-21

Valuation
Profitability
Growth
Health
P/E Ratio	-19.52
Forward P/E Ratio	-4.75
EPS	-0.54
1YR Price Target	23.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	100
Country	USA
Website	YMAB

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.

YMAB's peers: BLUE, PMCB, TCRR, RVMD, BDTX, BCEL, PASG, MRSN, ZNTL, TVTX, GBIO, KRON, ERAS, CCCC, EWTX, ARQT, ICVX, MIRM, VECT, DAWN, PCVX, LRMR, SNDX, MRUS, STRO, ZYME

*Chart delayed

Analyzing fundamentals for YMAB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see YMAB Fundamentals page.

Watching at YMAB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on YMAB Technicals page.